BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24468776)

  • 1. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.
    Bizerra FC; Jimenez-Ortigosa C; Souza AC; Breda GL; Queiroz-Telles F; Perlin DS; Colombo AL
    Antimicrob Agents Chemother; 2014; 58(4):2438-40. PubMed ID: 24468776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breakthrough invasive Candida glabrata in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC.
    Saraya T; Tanabe K; Araki K; Yonetani S; Makino H; Watanabe T; Tsujimoto N; Takata S; Kurai D; Ishii H; Miyazaki Y; Takizawa H; Goto H
    J Clin Microbiol; 2014 Jul; 52(7):2709-12. PubMed ID: 24789192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait.
    Al-Baqsami ZF; Ahmad S; Khan Z
    Sci Rep; 2020 Apr; 10(1):6238. PubMed ID: 32277126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.
    Pham CD; Iqbal N; Bolden CB; Kuykendall RJ; Harrison LH; Farley MM; Schaffner W; Beldavs ZG; Chiller TM; Park BJ; Cleveland AA; Lockhart SR
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4690-6. PubMed ID: 24890592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.
    Lewis JS; Wiederhold NP; Wickes BL; Patterson TF; Jorgensen JH
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4559-61. PubMed ID: 23817368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
    Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
    Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
    Beyda ND; John J; Kilic A; Alam MJ; Lasco TM; Garey KW
    Clin Infect Dis; 2014 Sep; 59(6):819-25. PubMed ID: 24879785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata.
    Singh-Babak SD; Babak T; Diezmann S; Hill JA; Xie JL; Chen YL; Poutanen SM; Rennie RP; Heitman J; Cowen LE
    PLoS Pathog; 2012; 8(5):e1002718. PubMed ID: 22615574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of multiple resistance profiles involving azoles, echinocandins and amphotericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungaemia.
    Cho EJ; Shin JH; Kim SH; Kim HK; Park JS; Sung H; Kim MN; Im HJ
    J Antimicrob Chemother; 2015 Apr; 70(4):1268-70. PubMed ID: 25550394
    [No Abstract]   [Full Text] [Related]  

  • 10. Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin.
    Durán-Valle MT; Gago S; Gómez-López A; Cuenca-Estrella M; Jiménez Díez-Canseco L; Gómez-Garcés JL; Zaragoza O
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3417-9. PubMed ID: 22391532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.
    Beyda ND; Liao G; Endres BT; Lewis RE; Garey KW
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5405-12. PubMed ID: 26100700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
    Zimbeck AJ; Iqbal N; Ahlquist AM; Farley MM; Harrison LH; Chiller T; Lockhart SR
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5042-7. PubMed ID: 20837754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.
    Bordallo-Cardona MÁ; Escribano P; de la Pedrosa EG; Marcos-Zambrano LJ; Cantón R; Bouza E; Guinea J
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Candida glabrata strains with reduced sensitivity to micafungin in vitro isolated from a patient with persistent Candidemia.
    Ishikawa T; Takata T; Akamatsu S; Hatakenaka K; Matsumoto S; Maki K; Ikeda F; Tamai R; Tamura K
    Jpn J Infect Dis; 2010 Sep; 63(5):332-7. PubMed ID: 20858999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough fungemia due to Candida fermentati with fks1p mutation under micafungin treatment in a cord blood transplant recipient.
    Konuma T; Takahashi S; Kiyuna T; Miharu Y; Suzuki M; Shibata H; Kato S; Takahashi S; Tojo A
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27859978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breakthrough invasive candidiasis in patients on micafungin.
    Pfeiffer CD; Garcia-Effron G; Zaas AK; Perfect JR; Perlin DS; Alexander BD
    J Clin Microbiol; 2010 Jul; 48(7):2373-80. PubMed ID: 20421445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
    Pfaller MA; Castanheira M; Lockhart SR; Ahlquist AM; Messer SA; Jones RN
    J Clin Microbiol; 2012 Apr; 50(4):1199-203. PubMed ID: 22278842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
    Shields RK; Nguyen MH; Press EG; Kwa AL; Cheng S; Du C; Clancy CJ
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4862-9. PubMed ID: 22751546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains.
    Denardi LB; Keller JT; Oliveira V; Mario DAN; Santurio JM; Alves SH
    Mycopathologia; 2017 Oct; 182(9-10):819-828. PubMed ID: 28493006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.